CION Ameerpet
Immunotherapy Cost & Access · Where the Money Goes
Why Immunotherapy Is So Expensive — And What the Price Is Actually Made Of
The number you were quoted has reasons behind it, and they are checkable ones. An immunotherapy antibody is grown inside living cells over weeks, kept at 2-8 °C every hour of its journey, and sold without a competitor for as long as its patent holds. That is most of the price. This page takes the figure apart line by line, so you can tell a high price from an unfair one. Every figure here is indicative, as of August 2026.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- It is grown, not manufactured — the molecule is a large protein produced inside living engineered cells over weeks, then purified and tested batch by batch.
- A patent means no second seller — while exclusivity holds there is nothing to price against; when it lapses and a biosimilar arrives, the price of that molecule moves.
- Two products, two very different prices — dose basis, vial fit, cycle interval and whether a biosimilar exists explain most of the gap between one immunotherapy and another.
- You are not being singled out — ask for the price of the exact product prescribed, in writing and dated, and compare it against what the same molecule costs elsewhere.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
The short answer
Why is immunotherapy so expensive?
Because it is a living-cell product sold without competition. The antibody is grown inside engineered cells over weeks, purified, tested batch by batch, and held cold every hour of its journey. While its patent holds, there is no rival product to price against. Manufacturing and exclusivity together explain most of the figure.
Families almost always arrive at this question the same way. A number is quoted. It is far larger than anything in the treatment so far. And nobody explains where it came from. That silence is what makes a high price feel like an unfair one. Usually it is not unfair, it is unexplained. Below is the figure taken apart: what each part pays for, and whether it can move.
| What you are paying for | Why it costs what it does | Does it change over time? |
|---|---|---|
| The molecule itself | A large protein grown inside engineered mammalian cells over several weeks, then purified through many stages. Every batch is tested, and a batch that fails is discarded, not sold. | Slowly, and mainly when a second approved manufacturer appears |
| The cold chain | The vial must stay between 2 and 8 °C from the manufacturing site to the infusion chair. Refrigerated transport, monitored storage and documented handling are all priced in. | Broadly stable |
| Patent and market exclusivity | While a molecule is under patent, only the originator may sell it in India. There is no second seller, so there is nothing for the price to compete against. | Sharply, at patent expiry |
| Research that never reached the market | Most cancer drug candidates fail somewhere in development. The price of the ones that reach patients carries the cost of the ones that did not. | Slowly |
| Dose, body weight and vial strength | Many immunotherapy doses are set by body weight, while vials come in fixed strengths. Part of a vial can go unused, and you are billed for the vial, not the millilitre. | Yes, a change of schedule or dosing basis changes this arithmetic |
| A small eligible population | Once biomarker testing is done, only a minority of Indian patients are candidates. Development cost is recovered across comparatively few people. | Slowly |
| Import, duty and distribution | A product manufactured abroad carries freight, customs duty and several distribution margins before it reaches a hospital pharmacy shelf. | Yes, local manufacture removes a large part of this |
| The monitoring attached to the drug | Day-care time, pre-cycle blood tests, thyroid and hormone checks and response-assessment imaging recur for as long as treatment continues. | Stable per cycle; the total scales with treatment length |
Immunotherapy is administered as day care at CION centres, so you come in, are treated, and go home the same day. Response-assessment PET-CT is coordinated at partner imaging centres, not owned by CION, and those scans are billed by the imaging centre directly.
Did you know?
The price of the drug is not the price of the treatment. Day-care administration, pre-cycle blood tests and reassessment scans typically add roughly 30-40% across a year — indicative, as of August 2026. Before you compare two quotes, check whether both include those lines, or neither does.
Grown, not synthesised
Why does an immunotherapy antibody cost more than chemotherapy?
Because a chemotherapy drug can be copied exactly and an antibody cannot. Chemotherapy is a small molecule built by chemical synthesis, so any qualified maker can produce an identical generic. An antibody is grown in living cells, so a rival can only make a highly similar biosimilar, and must prove that similarity before CDSCO will approve it.
This one difference explains more of the price gap than anything else. A generic can reach the market quickly once a patent expires, and prices fall hard. A biosimilar needs its own cell line, its own manufacturing plant, its own analytical comparability package and its own clinical data. That takes years and considerable capital. So competitors arrive slowly, and for some molecules they do not arrive at all.
| Feature | Standard chemotherapy (small molecule) | Immunotherapy antibody (biologic) |
|---|---|---|
| What the drug is | A small chemical molecule, a few dozen atoms | A large protein antibody, tens of thousands of atoms folded into a precise shape |
| How it is made | Chemical synthesis in a reactor; the same recipe gives the same molecule | Grown inside living engineered cells over weeks, then purified and tested batch by batch |
| Can a rival copy it exactly? | Yes, a generic is chemically identical | No, the closest possible is a highly similar version, called a biosimilar |
| What a copy must prove | Bioequivalence, through a comparatively short study programme | Analytical comparability plus its own clinical data, on the CDSCO similar-biologic pathway |
| Storage and handling | Often room temperature, and handling is routine | An unbroken 2-8 °C cold chain; one temperature excursion writes off the vial |
| What happens to the price when copies arrive | Usually a very large fall, and quickly | A smaller but still substantial fall, arriving years later |
None of this makes any particular quotation correct, and you should still check yours. What it does mean is that the price of immunotherapy is not set by a hospital deciding what a family can bear. The drug price is set upstream, at the manufacturer, and reaches you through pharmacy and distribution margins you are entitled to see itemised. What a hospital controls is the administration, monitoring and imaging around the drug, which is exactly why you should ask for those lines separately.
Two quotes, two different numbers
Why does one immunotherapy cost more than another?
Competition, mostly. Where an approved biosimilar of a molecule exists in India, that molecule costs materially less than one where the originator is still the only supplier. After that it is dosing basis, how the dose fits the vial, how often cycles fall, whether the product is imported, and the class of drug it belongs to.
- Whether an approved biosimilar of that molecule exists. This is the largest single difference between two otherwise comparable products, and it is worth asking about for your exact prescription.
- Imported or made in India. A locally manufactured biologic avoids the freight, customs duty and part of the distribution chain that an imported one carries.
- Weight-based or fixed dosing. A weight-based dose scales with the patient; a fixed dose does not. Which one applies changes what a cycle costs. See Weight-Based vs Fixed Dosing: Does It Change What You Pay?
- How the dose fits the available vial. Vials come in fixed strengths. A dose sitting just above one vial strength means paying for two, and that difference is real between products.
- How often cycles fall. A drug given every two weeks is billed more times in a year than one given every six, even where the per-cycle price looks similar.
- Given alone or alongside chemotherapy. A combination regimen carries the cost of both components, plus the supportive medicines the chemotherapy needs.
- Antibody or cell therapy. An antibody is produced in a large batch. A CAR-T cell therapy is manufactured individually for one patient, which is why it sits in an entirely different bracket. CION does not provide CAR-T or cell therapy, and where it is being considered patients are referred to centres that do.
One question separates a clear quotation from an unclear one: “what is the price of the exact product you have prescribed, and is there an approved alternative version of the same molecule?” Ask for the answer in writing, with the date on it. An undated price is not a price.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
See the Price Broken Down, Not Just Quoted
Our cost counsellors will separate drug, day care, monitoring and scans, and tell you plainly which parts you can influence and which you cannot.
What actually moves the price
Will immunotherapy prices come down in India?
For some molecules they already have. Prices move when patent protection lapses and an approved biosimilar enters. For one widely used checkpoint inhibitor, a domestically manufactured biosimilar launched in January 2026 at roughly a quarter of the reference product price. Other molecules remain protected. Plan against the price quoted to you today.
It is worth understanding the mechanism rather than waiting for a rumour to become true. Prices in this category do not drift downwards on their own. They step down when a specific regulatory or commercial event happens, and they stay flat in between.
| What moves the price | What it typically does | Where it stands, August 2026 |
|---|---|---|
| Patent expiry on a molecule | Opens the market to other approved manufacturers for the first time | Has already happened for one widely used checkpoint inhibitor, in May 2026; protection on another is expected to begin lapsing around 2028 to 2029 |
| The first approved biosimilar arrives | The single largest step down, because a second seller finally exists | One domestic biosimilar launched in January 2026 at roughly a quarter of the reference product price |
| A second and third biosimilar arrive | Further, smaller reductions as competition builds | Follows the first entrant, usually over years rather than months |
| Local manufacture instead of import | Removes freight, customs duty and part of the distribution margin | Applies to a growing number of biologics now made in India |
| Regulatory price action | Trade-margin caps and price control have been applied to some cancer medicines before | Product-specific; check the current position rather than assuming it applies |
| A change in schedule or dosing basis | Alters how many billed cycles fall in a year, and how much of a vial is used | A clinical decision for your treating team, never a purely financial one |
Two practical conclusions follow. First, ask specifically whether an approved biosimilar of your molecule is available in India today, because the answer differs by molecule and it changes the number more than anything else you can do. Second, do not delay a clinically indicated treatment while waiting for a price to fall. A patent timeline is not a treatment timeline, and cancer does not pause for either.
Before you chase a cheaper vial
Counterfeit checkpoint inhibitors have been reported entering the Indian supply chain ahead of patent expiry. A counterfeit vial is not a weaker medicine, it is an unknown substance going into a vein. A genuine product also has to have stayed between 2 and 8 °C for its entire journey, and an informal supplier cannot evidence that.
Buy only through the treating hospital pharmacy, or a licensed pharmacy your hospital accepts. Keep the invoice and the batch number. Ask the day-care nurse to check the vial and its cold-chain record before it is set up. If an offer is far below every other quotation you have seen, treat that as the warning it is, and take it to your oncologist rather than to the seller.
What you can influence
What can you actually do about the price?
Six things, none of which involve skipping cycles. Get an itemised dated estimate. Ask whether an approved biosimilar of your molecule exists. Ask how the dose fits the vial. Settle the scheme and insurance position before cycle one. Ask about trials. And say plainly if the money is not there.
- 1
Ask for the price of the exact product, in writing and dated
Drug, day care, monitoring bloods and scans on separate lines. A single lump figure cannot be checked against anything, and an undated one cannot be relied on next month.
- 2
Ask whether an approved biosimilar of this molecule exists in India
For one molecule the answer changed in January 2026. For others it has not changed yet. This is a question for your oncologist and the hospital pharmacy, never for a reseller.
- 3
Ask how the prescribed dose fits the available vial strengths
Where a dose sits relative to a vial decides how much you pay for medicine that is never given. Fixed-dose and weight-based schedules behave differently here, as Weight-Based vs Fixed Dosing: Does It Change What You Pay? sets out.
- 4
Settle the scheme and insurance position before cycle one
Ask the treating hospital’s scheme desk and the insurance desk, not the treating doctor. Many refusals are documentation problems rather than policy exclusions, and they are far easier to fix before treatment starts than after.
- 5
Ask whether a clinical trial fits the diagnosis
Some trials supply the study treatment at no drug cost. Eligibility is strict, enrolment is never promised, and a trial is not a discount scheme. It costs nothing to ask your oncologist whether one is open for your situation.
- 6
If the money is not there, say so before the first cycle
A treating team can plan around a stated constraint. It cannot plan around cycles that are quietly delayed or skipped, and delaying cycles to save money can change how the treatment works.
A note on schemes and ceilings. Under Telangana’s Aarogyasri scheme, certain immunotherapy packages may be covered up to scheme-defined ceilings. A ceiling caps what the scheme pays; it does not cap what the treatment costs, and anything above it, or outside the package, remains your family’s to meet. Empanelment, package contents and ceilings change over time, so confirm the current position with the treating hospital’s scheme desk. Private policies usually reimburse billed amounts within your sum insured, where sub-limits and the definition of day care decide how much is actually paid.
Nothing on this page says any scheme or insurer will cover your treatment. Coverage is decided on your individual documents and diagnosis. Two other routes are worth reading before you commit: Section 80DDB and Tax Relief on Immunotherapy Costs and Crowdfunding for Immunotherapy: What Actually Works.
Not starting is a real option, and a legitimate one. If the honest arithmetic says a family cannot sustain a course, that belongs in a conversation with the treating oncologist before the first cycle, not as a quiet default halfway through. There is usually more than one reasonable path, and the tumour board can be asked to look at all of them.
Costs explained, not defended
Decisions for Healing, Not Billing
A price you understand is a price you can plan around. We show you what each line is for, dated and in writing, before anything is decided.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Immunotherapy Pricing: Your Questions Answered
Why is immunotherapy so expensive compared to chemotherapy?
Because it is a fundamentally different thing to manufacture. Standard chemotherapy is a small chemical molecule built in a reactor, and once its patent expires any qualified manufacturer can produce an identical generic cheaply. An immunotherapy antibody is a large protein grown inside living engineered cells over several weeks, then purified and tested batch by batch, and held between 2 and 8 degrees Celsius from the factory to the infusion chair. A copy of it is never chemically identical, only highly similar, so it must complete its own comparability and clinical programme before CDSCO will approve it. That gap in manufacturing, in cold chain, and in how long a competitor takes to arrive is most of the price difference. Indicative, as of August 2026.
What actually drives the price of an immunotherapy drug?
Five things, in roughly this order. Living-cell manufacturing and the batch testing that goes with it. An unbroken 2 to 8 degree Celsius cold chain, where one temperature excursion writes off the vial. Patent exclusivity, which means there is no second seller to price against while it lasts. Research cost, because most oncology candidates fail and the ones that reach the market carry that burden. And dose arithmetic, because vials come in fixed strengths and a weight-based dose can leave part of a vial unused. Import duty and distribution margins sit on top for any product not manufactured in India. All indicative, as of August 2026.
Why does one immunotherapy drug cost more than another?
Mostly because of who else is allowed to sell it. Where an approved biosimilar of the same molecule exists in India, that molecule costs materially less than one where the originator is still the only supplier. After that it is dose basis and vial fit, whether the product is imported or made locally, and the cycle interval, since a drug given every two weeks is billed more times a year than one given every six. Drug class matters most of all: an antibody produced in a large batch is not priced like a cell therapy manufactured individually for a single patient. CION does not provide CAR-T or cell therapy. Indicative, as of August 2026.
Will immunotherapy become cheaper in India?
For some molecules it already has, and for others it has not yet. Prices move when patent protection on a molecule lapses and an approved biosimilar enters the market. For one widely used checkpoint inhibitor a domestically manufactured biosimilar launched in India in January 2026 at roughly a quarter of the reference product price, and the originator patent on that molecule lapsed in May 2026. Protection on another widely used checkpoint inhibitor is expected to begin lapsing around 2028 to 2029. Nobody can promise what a particular product will cost on the day you need it, so plan against the price quoted to you in writing today rather than a price you are hoping for. Indicative, as of August 2026.
Is it safe to buy immunotherapy cheaper from another source?
Not from a reseller or a grey-market supplier, no. Counterfeit checkpoint inhibitors have been reported entering the Indian supply chain ahead of patent expiry, and a counterfeit vial is not merely a weaker medicine, it is an unknown substance given into a vein. A genuine product also has to have stayed between 2 and 8 degrees Celsius for its entire journey, which an informal supplier cannot evidence. Buy only through the treating hospital pharmacy or a licensed pharmacy the hospital accepts, keep the invoice and the batch number, and ask the day-care nurse to check the vial and its cold-chain record before it is set up.
What does immunotherapy cost besides the drug itself?
Day-care administration on every cycle, blood tests before most cycles, periodic thyroid and hormone monitoring, response-assessment imaging every two to three months, and the treatment of any immune-related side effect. Response-assessment PET-CT is coordinated at partner imaging centres, not owned by CION, and is billed by them. Together these lines typically add roughly 30 to 40 per cent on top of the drug across a year. Travel to every cycle, a caretaker's leave and lost household income sit outside the hospital bill altogether. Ask for an itemised estimate with each line separated and the date written on it. Indicative, as of August 2026.